








































Lasmiditan inhibits calcitonin gene-related peptide
release in the rodent trigeminovascular system
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Kirk W. Johnsonb, Alexander H.J. Dansera, Carlos M. Villalónc, Antoinette MaassenVanDenBrinka,*
Abstract
Migraine headache pathophysiology involves trigeminovascular system activation, calcitonin gene-related peptide (CGRP) release, and
dysfunctional nociceptive transmission. Triptans are 5-HT1B/1D/(1F) receptor agonists that prejunctionally inhibit trigeminal CGRP release,
but their vasoconstrictor properties limit their use in migraine patients with cardiovascular disease. By contrast, lasmiditan is a novel
antimigraine and selective 5-HT1F receptor agonist devoid of vasoconstrictor properties. On this basis, this study has investigated the
modulation of trigeminal CGRP release by lasmiditan. For this purpose, we have comparatively analysed the inhibition of several
components of the trigeminovascular system induced by lasmiditan and sumatriptan through: ex vivo KCl-induced CGRP release from
isolated dura mater, trigeminal ganglion, and trigeminal nucleus caudalis of mice; and in vivo dural vasodilation in the rat closed-cranial
window model induced by endogenous (electrical stimulation and capsaicin) and exogenous CGRP. The ex vivo release of CGRP was
similarly inhibitedby sumatriptan and lasmiditan in all trigeminovascular systemcomponents. In vivo, intravenous (i.v.) lasmiditan or higher
doses of sumatriptan significantly attenuated the vasodilatory responses to endogenous CGRP release, but not exogenous CGRP
effects. These data suggest that lasmiditan prejunctionally inhibits CGRP release in peripheral and central trigeminal nerve terminals.
Because lasmiditan is a lipophilic drug that crosses the blood–brain barrier, additional central sites of action remain to be determined.
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1. Introduction
Migraine is a chronic neurovascular disorder characterized by
recurrent severe attacks of throbbing headache, which can be
accompanied by nausea, vomiting, photophobia, and phono-
phobia.30 Although the pathophysiology of migraine has not been
elucidated completely, it has been proposed that the headache
phase results from activation and sensitization of trigeminal
afferents frommeningeal nociceptors, neuropeptide release, and
dysfunctional nociceptive transmission.31
Calcitoningene-relatedpeptide (CGRP) isakeyneuropeptide,widely
expressed in the peripheral and central components of the trigemino-
vascular system, involved in craniofacial nociceptionmodulation.11,25,48
Infusion of CGRP triggers immediate headaches in healthy volunteers
and immediate headaches as well as delayed migraine-like attacks in
migraine patients.30 Moreover, during spontaneous migraine attacks,
this peptide is released in the extracerebral circulation.15 Moreover,
blocking CGRP or its receptor with monoclonal antibodies, which do
not cross the blood–brain barrier, has revealed that migraine attacks
can be prevented through peripheral blockade of CGRP.16,44
For almost 30 years, the triptans, 5-HT1B/1D receptor agonists, of
which some also display affinity for the 5-HT1F receptor,
41 have been
the specific treatment of choice for terminating migraine attacks. It
has previously been shown that during a migraine attack, triptans
normalize the elevated CGRP plasma levels by inhibiting further
release from trigeminal afferents and, consequently, decrease
nociceptive transmission from the periphery to the central nervous
system.14However, due to their peripheral vasoconstrictor potential,
including coronary vasoconstriction, they are contraindicated in
migraine patients with cardiovascular diseases.35 This problem led
to the search for antimigraine agents lacking vasoconstrictor activity,
which culminated in the development of lasmiditan.
Lasmiditan is a novel high-affinity, lipophilic, highly selective
5-HT1F receptor agonist (“ditan,” Table 1) that is currently under
development for the acute treatment of migraine.37 Phase III trials
revealed clinical efficacy in migraine patients, and preclinical data
showed that it is devoid of vasoconstrictor properties in several
blood vessels including human isolated coronary arteries.40
However, few studies have investigated its exact (antimigraine)
mechanism(s) of action. Lasmiditan may possess central as well
as peripheral antinociceptive effects because it reduced c-Fos
expression in the trigeminal nucleus caudalis and inhibited the
dural plasma protein extravasation, both induced by electrical
stimulation of the trigeminal ganglion.37 However, the latter effect
has not been demonstrated to occur in migraine patients, and
several plasma protein extravasation inhibitors failed to be
effective in clinical trials.10 Therefore, based on the neurobiology
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of migraine headache, we set out to analyze the effects of
lasmiditan on peripheral components as well as central projections
of the trigeminovascular CGRPergic system, and compared our
results with the responses to sumatriptan, as a positive control. For
this purpose, we investigated the ex vivo CGRP release in the
peripheral (dura mater and trigeminal ganglion) and central
(trigeminal nucleus caudalis) trigeminal components of mice, as
well as the dural vasodilation induced by endogenous (capsaicin
and electrical stimulation) and exogenousCGRP in rats in vivo. Our
results show that selective 5-HT1F receptor activation by lasmiditan
inhibits CGRP release and, consequently, may attenuate nocicep-
tive transmission in the trigeminovascular system.
2. Material and methods
2.1. Experimental animals
Experiments were performed in 36 male C57BL/6J (22-24 g; 13-
14 weeks of age) mice and 54male Sprague-Dawley (300-350 g;
8-10 weeks of age) rats, purchased from Charles River. Animals
were housed under a 12-hour dark–light cycle in a special room at
constant temperature (22 6 2˚C) and humidity (50%), with free
access to food and water. Only male animals were used to avoid
the well-known interaction of CGRP with cycling estrogen,29
previously reported in the cranial-window model.22 All exper-
imental protocols of the study were approved by the Erasmus
University Medical Center’s institutional animal ethics committee
(permission protocol numbers EMC 2891/3393), in accordance
with the European directive 2010/63/EU and ARRIVE (Animal
Research: Reporting In Vivo Experiments) reporting guidelines for
the care and use of laboratory animals. All animals were randomly
assigned into the different experimental protocols. For the CGRP
assays (see next section), the analyst was not blinded to the
compounds but to the research hypothesis. For the in vivo
experiments, values were calculated using the dose–response
autoanalyse selection feature of LabChart.
2.2. Ex vivo: calcitonin gene-related peptide release in
trigeminal nucleus caudalis, trigeminal ganglion, and
dura mater
This technique has been previously reported8; in brief, mice were
anesthetized using intraperitoneal (i.p.) sodium pentobarbital
(80 mg/kg) and decapitated at the atlanto-occipital joint. The
scalp was retracted from the cranium. First, the trigeminal caudal
nuclei, which run 9 to 13mmcaudally from bregma, were isolated
from the brainstem. The skull was divided into halves by a clear
cut along the sagittal suture, and the cerebral hemispheres were
carefully removed while the cranial dura was left attached to the
skull. Second, the trigeminal ganglia were harvested by
dissection 1 mm proximal and distal to the point where the
mandibular nerve branches off. Third, the remaining brain tissues
were extracted from the hemisected skulls without damaging the
dura of the middle cranial fossa. Each trigeminal nucleus
caudalis, trigeminal ganglion, and hemisected skull with the dura
mater were immersed and washed in carbogenated synthetic
interstitial fluid, containing (mM): NaCl (108), KCl (3.48), MgSO4
(3.5), NaHCO3 (26), NaH2PO4 (11.7), CaCl2 (1.5), sodium
gluconate (9.6), glucose (5.55), and sucrose (7.6) for 30 minutes
at 37˚C. The isolated tissueswere randomized and placed in a 24-
well plate containing 500-mL synthetic interstitial fluid. The 24-
well plate was fixed in a water bath that formed a closed humid
chamber of 37˚C. Basal CGRP values were measured in each
tissue; then, CGRP release was induced by superfusion with 60-
mMKCl. Vehicle (saline), sumatriptan, or lasmiditan (30 mM each,
concentration based on our earlier experiments with sumatriptan)
8 was applied 10 minutes before the challenge with 60-mM KCl.
For every sample, including the baseline measurement, the
solution was collected after 10-minute incubation andmixed with
aprotinin (500 KIU/mL). For the assessment of CGRP content,
samples were stored at220˚C until processedwith a commercial
CGRPRIA kit according to themanual (Phoenix Pharmaceuticals,
Burlingame, CA). Calcitonin gene-related peptide (pg/mL)
absorbance values were calculated through an interpolation
method using an equation derived from the standard curve. The
assay has a detection level of ;0.1 pg/mL. Blank wells without
CGRP were used as a control to exclude possible false-positive
measurements, as previously described.21
2.3. In vivo: intravital microscopy and dural
artery vasodilation
Rats were anaesthetized throughout the experiments using
sodium pentobarbital (60 mg/kg, i.p. followed by 18 mg/kg
intravenously [i.v.] per hour). The adequacy of anesthesia was
judged by a negative tail flick test, mean arterial pressure levels,
and the absence of ocular reflexes, among others. Tracheal
intubation was performed, and a capnograph was used to
monitor pCO2 levels. As previously described,
50 the femoral vein
and artery were cannulated for i.v. administration of drugs and for
continuous monitoring of mean arterial pressure, respectively.
During the experiment, the core temperature of each animal was
maintained between 36.5˚C and 37.5˚C using a homeothermic
blanket system for rodents (Harvard Instruments, Edenbridge,
United Kingdom). Subsequently, the rat was placed in a stereo-
taxic frame, and the parietal bone was drilled thin until the dural
middle meningeal artery was clearly visible. Because the rat skull
Table 1
Summary of functional (pEC50 values of cAMP assays) and binding (pIC50 values of radioligand binding assays) data of
sumatriptan and lasmiditan at 5-HT receptors.
Compound Species Receptor
5-HT1B 5-HT1D 5-HT1F 5-HT7
pEC50 pIC50 pEC50* pIC50 pEC50 pIC50 pEC50 pIC50
Sumatriptan succinate Rat 6.44 7.26† 7.57 7.7 ND 7.2 ND 6.3†
Human 7.32 7.81 8.30 8.31 8.03 7.13 5.22 6.10
Lasmiditan hemisuccinate Rat ND ,5 ND ,5 ND 8.48 ND ND
Human ,5 5.98† 6.64 5.87† 8.43 8.66† ,5 ,5.52†
Data for sumatriptan40 and lasmiditan37 human recombinant 5-HT receptors. Data for lasmiditan rat 5-HT1 receptors.
27 Data for sumatriptan rat 5-HT1B,
4,13,19 5-HT1D,
43 5-HT1F,
33 and 5-HT7 receptors.
45
* pEC50 values correspond to [
35S] GTPgS assay.
† pKi; ND: no data were available.
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is thin, care was taken to drill with constant application of ice-cold
saline. The drilled area was covered with saline to prevent drying
of the skull and to facilitate visualization of the artery. The dural
artery diameter was captured with an intravital microscope (Leica
MZ 16; Leica Microsystem Ltd, Heerbrugg, Switzerland), using
a cyan filter on a cold light source. A zoom lens (80-400x
magnification) and camera (DCx V3.52, Thorlabs LTD, Ely, United
Kingdom) were used to capture the image of the dural artery,
which was displayed and measured on a computer using
a dedicated software package (IDA-Intravital Dimension Analy-
ser; http://www.beneryx.co.uk) integrated with a ADC/DAC
board (DI-158, DATAQ instruments, ’s-Hertogenbosch, The
Netherlands). Dural artery diameter was calculated from the area
under the curve of the intensity measured and expressed in
arbitrary units. For periarterial electrical stimulation, a bipolar
stimulating electrode (NE 200X, Clark Electromedical, Eden-
bridge, Kent, United Kingdom) was placed on the surface of the
bone approximately 200 mM from the artery. The surface of the
cranial window was stimulated at 5 Hz, 1 ms for 10 seconds
(Stimulator model S88, Grass Instruments, West Warwick, RI)
with a current intensity of 100 mA (monitored on an oscilloscope,
model 54601A; Hewlett Packard, Palo Alto, CA) and increasing
with 50-mA steps until a maximal level of vasodilation was
achieved, usually at 200 mA.23 Data of dural artery diameter and
mean arterial blood pressure were recorded using a LabChart
data acquisition system (AD Instruments Ltd, Oxford, United
Kingdom). Dural artery vasodilator responses produced by
periarterial electrical stimulation (100-200 mA), capsaicin (10
mg/kg, i.v.), or exogenous a-CGRP (1 mg/kg, i.v.) were elicited
before and after consecutive i.v. bolus injections of vehicle
(saline), sumatriptan, or lasmiditan (0.3, 1, 3, and 10mg/kg each).
These doses were based on clinically relevant doses previously
calculated40 as well as, for sumatriptan, previous studies
performed in the same model.50 In brief, for sumatriptan,
assuming a 25 to 100 mg oral dose in a 70-kg adult with a 15%
bioavailability would be equivalent to i.v. doses of about 0.05 to
0.21 mg/kg. For lasmiditan, a 50 to 200 mg oral dose in a 70-kg
adult with a 40% bioavailability would be equivalent to i.v. doses
of about 0.28 to 1.14 mg/kg. Each dose of the aforementioned
compounds was administered 5 minutes before a subsequent
treatment with electrical stimulation, capsaicin, or CGRP. Dural
artery diameter and mean arterial pressure values, were both
restored to preinjection levels by the time the next vasodilation
was induced, and 30minutes was allowed to elapse after each of
the vasodilator treatments for the recovery of baseline diameter.
2.4. Statistical analysis
All data are expressed as mean 6 SEM. Calcitonin gene-related
peptide release in the different trigeminal components of themice
was expressed as relative stimulated CGRP release, which was
calculated by the ratio of KCl-induced CGRP release and basal
CGRP values.12 Statistical differences of the basal CGRP values,
the relative stimulated CGRP release in the presence of vehicle,
and the % inhibition of CGRP release between groups were
calculated using a one-tailed Mann–Whitney test for unpaired
observations, as previously described.8 For comparing the
relative stimulated CGRP release in the presence of vehicle to
its corresponding treatment (sumatriptan or lasmiditan), a one-
tailed Wilcoxon matched-pairs test for nonparametric analysis of
paired was used. The peak changes in dural artery diameter were
expressed as percent change from baseline. Changes in mean
arterial pressure were expressed in absolute values (mmHg). The
differences between the variables within one group of animals
were compared by using a one-way repeated-measures analysis
of variance followed by Dunnett test. Statistical significance was
accepted at P , 0.05.
2.5. Compounds
The compounds used in this study (obtained from the sources
indicated) were: rata-CGRP (NeoMPSS.A., Strasbourg, France);
sumatriptan succinate and capsaicin (Sigma Chemical, Co,
Steinheim, Germany); and lasmiditan hydrochloride (provided
by Eli Lilly & Co, Indianapolis, IN). Calcitonin gene-related peptide,
sumatriptan, and lasmiditan were dissolved in physiological
saline. Capsaicin (1 mg/mL) was dissolved in a mixture of
Tween-80, ethanol 70%, andwater (1:1:8). The dosesmentioned
in the text refer to the free base of substances in all cases.
3. Results
3.1. Ex vivo: basal calcitonin gene-related peptide levels and
relative stimulated calcitonin gene-related peptide release
after KCl stimulation
A total of 108 tissues were analyzed. Tissues with basal CGRP
measurement errors (CGRP below detection limit, n 5 2) or that
did not generate CGRP release in response to 60mMKCl (n5 14)
were excluded. In addition, in one experiment, the positive control
(inhibition of CGRP by sumatriptan) failed (instead we measured
an increase in CGRP release of .15 times); this measurement
was a statistically significant outlier (P5 0.016, Dixon outlier test)
and was therefore excluded. Because data were paired between
the left side and right side, in these cases, both the left and right
sides were excluded.
There were no significant differences between the basal CGRP
levels from the left and right side components of the trigeminovas-
cular system in each experimental group (data not shown).
Moreover, basal CGRP levels (in absolute values; pg/mL) were
not different between the sumatriptan (S) and lasmiditan (L) groups
in the dura mater (S: 10.7 6 1.8 vs L: 9.7 6 3.0; n 5 10 and 9
respectively; P 5 0.302), trigeminal ganglion (S: 14.7 6 3.3 vs L:
18.4 6 10.2; n 5 12 each; P 5 0.130), and trigeminal nucleus
caudalis (S: 25.9 6 13.2 vs L: 48.5 6 21.9; n 5 10 and 9
respectively; P5 0.219). Moreover, the basal CGRP release values
were not modified by the incubation per se of vehicle, sumatriptan,
or lasmiditan in all the components of the trigeminovascular system
studied (data not shown). The relative stimulated CGRP release (ie,
the fold increase compared to baseline) induced by KCl in the
presence of vehicle (control) was comparable between both groups
in the dura mater (S: 6.0 6 1.4 vs L: 6.4 6 1.2; n 5 10 and 9,
respectively; P5 0.275), trigeminal ganglion (S: 5.46 1.5 vs L: 7.4
6 2.6; n5 12 each;P5 0.267), and trigeminal nucleus caudalis (S:
9.26 2.8 vs L: 10.96 3.0; n5 10 and 9 respectively; P5 0.330).
3.2. Ex vivo: relative stimulated calcitonin gene-related
peptide release in the presence of sumatriptan
and lasmiditan
The effects of pretreatment with sumatriptan or lasmiditan (30 mM)
on CGRP release in the trigeminovascular components are shown
in Figure 1. In the presence of sumatriptan, relative stimulated
CGRP releasewas significantly attenuated in the duramater (6.06
1.4 vs 3.06 0.5; n5 10;P5 0.032), trigeminal ganglion (5.46 1.5
vs 2.26 0.6; n5 12; P5 0.013), and trigeminal nucleus caudalis
(9.26 2.8 vs 2.86 0.7; n 5 10; P 5 0.032).
Moreover, lasmiditan also significantly attenuated the relative
stimulatedCGRP release in the duramater (6.46 1.2 vs 2.66 0.5;
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n5 9; P5 0.027), trigeminal ganglion (7.46 2.6 vs 2.16 0.7; n5
12 P5 0.032), and trigeminal nucleus caudalis (10.96 3.0 vs 3.6
6 1.1; n 5 9; P 5 0.037). Furthermore, both compounds were
equieffective in inhibiting CGRP release in the dura mater (S: 50%
vs L: 59%; n5 9-10; P5 0.257), trigeminal ganglion (S: 59% vs L:
71%; n5 12; P5 0.244), and trigeminal nucleus caudalis (S: 70%
vs L: 67%; n 5 9-10; P 5 0.275).
3.3. In vivo: effects of ES, capsaicin, and calcitonin gene-
related peptide onmean arterial pressure anddural diameter
At the beginning of the experiments, the average mean arterial
pressure from all animals was 99 6 2 mm Hg. Because there
were no significant differences on the hemodynamic and dural
artery changes in the control interventions (ES, capsaicin, and
CGRP) between groups, data were pooled for further analysis. In
none of the experiments, periarterial ES (100-200 mA) affected
the mean arterial pressure. By contrast, there was a significant
decrease in mean arterial pressure as compared to baseline after
the i.v. administration of 10 mg/kg capsaicin (276 5 mmHg, n5
19) or 1 mg/kg CGRP (29 6 4 mm Hg, n 5 14), which was not
different between capsaicin and CGRP (P5 0.744). At the end of
the experiments, the value of mean arterial pressure (976 2 mm
Hg) was not significantly different from the initial baseline value
(P 5 0.140; n 5 53).
3.4. In vivo: dural artery dilation induced by electrical
stimulation, capsaicin, and calcitonin gene-related peptide
Periarterial ES (100-200 mA) increased dural artery diameter by
62 6 3% (n 5 20), whereas i.v. administration of 10 mg/kg
capsaicin or 1 mg/kg CGRP increased the diameter by 59 6 3%
(n 5 20) and 666 3% (n 5 14), respectively. In accordance with
our previous controls, repeated treatment (up to 5 times) with
electrical stimulation (P 5 0.349; n 5 4), capsaicin (P 5 0.878;
n 5 4), or CGRP (P 5 0.912; n 5 4) produced reproducible
increases in dural artery diameter.
3.5. In vivo: effects of sumatriptan and lasmiditan per se on
mean arterial pressure and dural diameter
Because there were no significant differences on the hemody-
namic and dural artery effects among sumatriptan (or lasmiditan)
doses in the experimental interventions, data were pooled for
further analysis. As shown inFigure 2 (upper panels), sumatriptan
injection produced a significant (P, 0.0001, n5 21) short-lasting
and dose-dependent vasodepressor response starting at clini-
cally relevant doses. After each injection, mean arterial pressure
returned to baseline values before the next systemic vasodilation
was elicited. By contrast, lasmiditanwas devoid of significant (P5
0.274, n5 20) effects onmean arterial blood pressure at all doses
tested. When considering dural artery diameter (Fig. 2; lower
panels), all doses of sumatriptan significantly (P, 0.0001, n5 21)
and dose-dependently increased the artery diameter, whereas
lasmiditan only increased it significantly (P5 0.006, n5 20) after
injecting the 2 highest doses.
3.6. In vivo: effects of sumatriptan and lasmiditan on dural
artery dilation induced by electrical stimulation, capsaicin,
and calcitonin gene-related peptide
As shown in Figure 3, as compared to their corresponding
control, the pretreatment with high doses (3 and 10 mg/kg) of
sumatriptan significantly inhibited the vasodilation induced by
electrical stimulation (control increase in dural artery diameter: 60
6 3%vs 3mg/kg: 306 3%; 10mg/kg: 216 2%;P, 0.0001; n5
8) and capsaicin (control: 656 6% vs 3 mg/kg: 446 3%; 10 mg/
kg: 34 6 3%; P , 0.0001; n 5 8). By contrast, i.v. dural artery
diameter responses to exogenous (i.v.) CGRP were not affected
by any dose of sumatriptan (P 5 0.210; n 5 5).
In contrast to sumatriptan, already lower doses of lasmiditan
induced a significant dose-dependent attenuation of the vaso-
dilator responses to electrical stimulation (control increase in
dural artery diameter: 616 2% vs 0.3 mg/kg: 416 4%; 1 mg/kg:
396 3%; 3 mg/kg: 346 3%; 10mg/kg: 216 2%; P, 0.0001; n
5 8) and capsaicin (control: 56 6 5% vs 0.3 mg/kg: 38 6 7%; 1
mg/kg: 31 6 5%; 3 mg/kg: 30 6 5%; 10 mg/kg: 23 6 4%; P ,
0.0001; n 5 8) as compared to their corresponding control.
Similar as with sumatriptan, the exogenous CGRP responses
were not affected by any dose of lasmiditan (P 5 0.911; n 5 5).
4. Discussion
In this study, we investigated the potential antimigraine site of
action of the selective 5-HT1F receptor agonist lasmiditan in relation
to the trigeminovascular CGRPergic system, through inhibition of
chemically induced (KCl and capsaicin, through voltage-gated
calcium and TRPV1 channel activation, respectively) and electri-
cally induced CGRP release from trigeminal sensory fibers.
We compared our results with data obtained with sumatriptan
because this was the first triptan developed, and this class of
drugs is the current gold standard for the specific acute treatment
of migraine attacks. In accordance with our previous work,8
pretreatment with 30-mM sumatriptan attenuated KCl-relative
stimulated CGRP release in the peripheral and central compo-
nents of the trigeminovascular systemofmice ex vivo (Fig. 1). This
Figure 1. Relative stimulated CGRP release after KCl in the absence (2) or presence of sumatriptan (S) and lasmiditan (L) in the dura mater (n5 9-10), trigeminal
ganglion (n 5 12), and trigeminal nucleus caudalis (n 5 9-10). *P , 0.05 vs vehicle response. CGRP, calcitonin gene-related peptide.
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inhibition has previously been shown to be mediated through
activation of 5-HT1D and 5-HT1F receptors in rats, whereas
a lower concentration (3 mM) of sumatriptan was ineffective.3
Moreover, 30-mM lasmiditan was equieffective in attenuating
CGRP release in the dura mater, trigeminal ganglion, as well as
trigeminal nucleus caudalis; however, because theoretically
multiple 5-HT1 (ie, 5-HT1A and 5-HT1F) inhibitory-Gi protein
receptor subtypes expressed in the mice trigeminovascular
system7 could be activated at the nonselective concentration
used,40 we performedmore in-depth experiments with a range of
clinically relevant doses in the in vivo rat closed cranial window, an
experimental neurovascular model of migraine.50
In accordance with the ex vivo experiments, high doses (3 and
10 mg/kg) of sumatriptan were required to inhibit the neurogenic
dural vasodilation in response to i.v. capsaicin and periarterial
electrical stimulation. These high-dose inhibitory effects have
been previously shown with sumatriptan, and also with riza-
triptan, whereas low doses of both compounds (1 mg/kg) were
ineffective in this model.50,51 Based on data available on receptor
affinity profiles and pharmacological antagonism,5,41 the in-
hibition of CGRP release by triptans seems to be mediated
through activation of 5-HT1D and possibly also 5-HT1F receptors;
unfortunately, highly selective antagonists for the 5-HT1F recep-
tors are not yet commercially available to further determine the
receptor(s) involved. Remarkably, lasmiditan inhibited the neuro-
genic dural vasodilation in response to i.v. capsaicin and
periarterial electrical stimulation starting at lower, clinically
relevant doses; this effect is most likely mediated by selective
activation of the 5-HT1F receptor. By contrast, like sumatriptan,
lasmiditan was not capable of attenuating the nonneurogenic
dural vasodilation in response to exogenous CGRP. Thus, we
demonstrate that lasmiditan prejunctionally inhibits the release of
CGRP from trigeminal sensory fibers innervating the dural
vasculature.
The activation of either 5-HT1B, 5-HT1D, or 5-HT1F receptors on
trigeminal fibers results in a direct inhibition of adenylyl cyclase
and a subsequent decrease in the cAMP-signaling pathway,1
which in turn alters the phosphorylation of TRPV1 channels6 and
decreases the release of CGRP, as evidenced by the inhibition of
CGRP- and capsaicin-induced dural vasodilation by sumatriptan
and lasmiditan. In addition, activation of 5-HT1 receptors also
inhibits neurotransmitter release occurring after stimulation with
KCl or electrical stimulation.8,18,20 However, if both compounds
act through the same second messenger cascade, why does
agonism of the 5-HT1F receptor seem to be more effective?
Although the mRNA expression of the 5-HT1D and 5-HT1F
receptors has been detected in the peripheral and central
components of the rat trigeminovascular system,3 and both
receptors have been found to be colocalized with CGRP,2,34
a small study (n 5 3) found that the 5-HT1D receptor is more
abundantly expressed in the trigeminal ganglion, whereas the
highest concentration of 5-HT1F receptors was found in the
trigeminal nucleus caudalis, and this expression pattern could
result in diverse inhibition profiles.3 However, more in-depth
studies have found that the 5-HT1B, 5-HT1D, and 5-HT1F
receptors are equally expressed in the trigeminal ganglion.9,39
Therefore, the difference between sumatriptan and lasmiditan
inhibition results does not seem to be explained by the
expression/density profile of the 5-HT1B/1D/1F receptors, and may
involve (although this study does not prove it) drug-dependent
Figure 2. Effects per se of increasing doses of sumatriptan or lasmiditan on mean arterial pressure (MAP) and dural artery diameter. n 5 20 to 21. *P , 0.05 vs
vehicle response.
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factors such as the affinity and intrinsic activity of these
compounds for each of these receptors at the specific
components of the trigeminovascular system.
It is noteworthy that species differences have been described
for the 5-HT1 receptor subtypes mediating the inhibition of
trigeminal CGRP release by 5-HT1B and 5-HT1D receptor
agonists (including sumatriptan). This inhibition has previously
been attributed to activation of 5-HT1B receptors in rats andmice,
and 5-HT1D receptors in guinea pigs, cats, and humans.
49
Moreover, the rat and mouse 5-HT1B receptor has been
considered to represent the counterpart to the 5-HT1D receptor
in other species.24 Thus, sumatriptan’s receptor affinity for the
5-HT1 receptors in rats (5-HT1D.5-HT1B) correlates with the high
doses required to inhibit CGRP release through 5-HT1B receptors
Figure 3.Effects of increasing doses of sumatriptan or lasmiditan on the vasodilation of the dural artery induced by electrical stimulation (upper panels, n5 8 each),
capsaicin (middle panels, n 5 8 each), and CGRP (lower panels, n 5 5 each). *P , 0.05 vs vehicle response. CGRP, calcitonin gene-related peptide.
May 2020·Volume 161·Number 5 www.painjournalonline.com 1097
and, possibly also, 5-HT1F receptors. In addition, as described
above, the CGRPergic system is influenced by cycling estrogen,
which we have previously described in both the human26 and
rodent22 trigeminovascular system, whereas a link between
testosterone and CGRP release remains to be demonstrated.
Thus, in future studies, it would be interesting to investigate the
effects of lasmiditan on trigeminovascular CGRP release in
female animals with different hormonal status, but also in male
animals that are intact or orchiectomized.
It should be kept in mind that our rodent model is suitable for
studying inhibition ofCGRP release, but not hemodynamic changes
in response to 5-HT1 receptor stimulation. In support of this is the
fact that lower doses of i.v. sumatriptan immediately activated
systemic vascular 5-HT receptors before reaching the 5-HT1D (and
later 5-HT1B) receptors in the trigeminal sensory fibers. Conse-
quently, the injection of already clinically relevant doses of
sumatriptan resulted in a significant drop in mean arterial pressure
and dural artery vasodilation (rather than vasoconstriction; Fig. 2),
which have been shown to bemediated through activation of 5-HT7
receptors in rodents.46 However, as previously pointed out, rodents
are not suitable for studying hemodynamic changes associated
with 5-HT1 receptor activation because receptor expression and
vascular responses are not similar to nonrodent species, including
humans. Hence, we have recently addressed the vasoconstrictor
effects of sumatriptan in appropriate and translational (human
isolated arteries and canine in vivo)models.40 Similar to our previous
findings, i.v. infusions of sumatriptan, through 5-HT1B receptor
activation,32 increased systemic and pulmonary arterial pressure in
humans,36 which represents a major limitation for triptans use in
cardiovascular compromised patients. By contrast, lasmiditan was
devoid of hemodynamic effects at all doses tested. Thus, as
demonstrated by the above-mentioned studies, clinically relevant
doses of lasmiditan are not associatedwith changes inmean arterial
pressure or dural artery diameter. These results suggest that the
antimigraine efficacy of lasmiditan is unrelated to direct vasocon-
strictive mechanisms, although the inhibition of CGRP release may
indirectly affect dural artery diameter.
The 5-HT1F receptor is also widely expressed throughout the
central nervous system, and because lasmiditan is a lipophilic
drug that crosses the blood–brain barrier (in contrast with
sumatriptan), it has been associated with mild central side
effects. The most common side effects described in clinical trials
are dizziness, paresthesia, somnolence, fatigue, nausea, and
lethargy.17,28 Given that lasmiditan inhibits the peripheral
components of the trigeminovascular system, it is tempting to
speculate what would happen to the side-effect profile or
antimigraine efficacy of a selective 5-HT1F receptor agonist that
does not enter the brain. Whether inhibiting the trigeminovascular
system centrally as well as peripherally is more effective than just
peripherally or centrally, or whether a mixed mechanism is
associated with increased side effects remains to be determined.
Unfortunately, there are no hydrophilic (selective) 5-HT1F receptor
agonists available yet.
Additional (antimigraine) mechanisms of action described with
previous 5-HT1F receptor agonists include modulation of
glutamate release from trigeminal sensory fibers and mitochon-
drial biogenesis.38,42 Clearly, future experiments, beyond the
scope of our study, are needed to determine whether lasmiditan
can inhibit glutamatergic neurons in the central nervous system
and/or enhance mitochondrial biogenesis. Moreover, it would be
interesting to evaluate whether lasmiditan is able to attenuate
cortical spreading depression, a key pathogenic event inmigraine
with aura,47 and whether these mechanisms are also associated
with its clinical antimigraine efficacy.
In conclusion, our results indicate that lasmiditan prejunction-
ally inhibits CGRP release in peripheral and central trigeminal
nerve terminals. This effect may, at least partly, explain the clinical
efficacy of lasmiditan. Because activation of 5-HT1F receptors is
not associated with vasoconstriction, lasmiditan may represent
a cardiovascular safety advantage over the vasoactive triptans.
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